Table 3
Reports of micrometastases and survival in patients with Dukes’s B colorectal cancer
| Ref | No patients | % Patients with MM | Lymph nodes/pt* | Positive nodes/pt | Follow up (months) | IHC markers | Result |
|---|---|---|---|---|---|---|---|
| *Mean (SD). | |||||||
| CEA, carcinoembryonic antigen; CK, cytokeratin; EMA, epithelial membrane antigen; IHC, immunohistochemistry; MM, micrometastases; NS, not significant; pt, patient; S, significant; TAG-72, tumour associated glycoprotein-72. | |||||||
| 13 | 100 | 39% | 4.7 | 2.0 | 57 | CK8/18/19 | NS |
| 17 | 93 | 31% | 19.4 | 1.8 | 66 | CK MNF 116 | NS |
| 18 | 77 | 25% | 7.2 | NA | 120 | CK AE1/AE3 | NS |
| 19 | 46 | 26% | 13 | 2.0 | 60 | CEA, CK AE1/AE3 | NS |
| 14 | 50 | 28% | 11.3 | 2.3 | 66 | CK AE1/AE3; TAG-72 | S |
| 15 | 100 | 34% | 11.5 | NA | 42 | CK20 (PCR) | S |
| 16 | 42 | 21.4% | 15.3 | 2.1 | 120 | CK8/18 | S |
| Our study | 106 | 41% | 14 (8.4) | 2.2 | 85 | CK AE1/AE3; CK8/18 | NS |
